Back
#1
34.2%
Top 0.2%
12.1%
Top 32%
7.1%
Top 80%
5.5%
Top 1%
4.3%
Top 2%
4.3%
Top 5%
3.1%
Top 34%
2.1%
Top 27%
1.7%
Top 0.5%
1.7%
Top 2%
1.7%
Top 3%
1.5%
Top 1%
1.5%
Top 9%
1.0%
Top 2%
0.8%
Top 1%
0.8%
Top 1%
0.8%
Top 27%
0.5%
Top 24%
0.5%
Top 20%
0.5%
Top 9%
0.5%
Top 6%
0.5%
Top 13%
0.5%
Top 17%
0.5%
The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose
2021-09-23
hematology
Title + abstract only
View on medRxiv
Show abstract
Immunization with mRNA SARS-CoV-2 vaccines has been highly recommended and prioritized in fragile categories with higher risk of mortality after COVID-19 disease compared to healthy people, including patients with myelofibrosis (MF). Available data on the vaccine immune response developed by MF patients, and the impact of the treatment with the inhibitor of JAK-STAT signaling ruxolitimib, are still fragmented to support an informed decision for a third dose for this category of subjects. Here, w...
Predicted journal destinations
1
Frontiers in Immunology
140 training papers
2
Blood Advances
16 training papers
3
Scientific Reports
701 training papers
4
PLOS ONE
1737 training papers
5
JCI Insight
63 training papers
6
Vaccines
131 training papers
7
Frontiers in Medicine
99 training papers
8
Nature Communications
483 training papers
9
eLife
262 training papers
10
Biomedicines
21 training papers
11
Journal of Clinical Investigation
50 training papers
12
Cell Reports Medicine
49 training papers
13
Science Advances
52 training papers
14
iScience
74 training papers
15
Cell
28 training papers
16
Biology Methods and Protocols
19 training papers
17
The Journal of Immunology
19 training papers
18
Journal of Clinical Medicine
77 training papers
19
Nature Medicine
88 training papers
20
Heliyon
57 training papers
21
International Journal of Molecular Sciences
39 training papers
22
Science Translational Medicine
40 training papers
23
Viruses
79 training papers
24
eBioMedicine
82 training papers